NCR Online Journal

Propulsion of Psoriasis Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Treatment Domain | Major Companies – Bristol-Myers Squibb, Amgen, GSK, and Others

 Breaking News
  • No posts were found

Propulsion of Psoriasis Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Treatment Domain | Major Companies – Bristol-Myers Squibb, Amgen, GSK, and Others

April 18
23:49 2023
Propulsion of Psoriasis Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Treatment Domain | Major Companies - Bristol-Myers Squibb, Amgen, GSK, and Others

DelveInsight’s, “Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including Psoriasis clinical trials and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Psoriasis pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, Psoriasis clinical trials studies, Psoriasis NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key Takeaways from the Psoriasis Pipeline Insight Report

 

  • Over 80+ Psoriasis Companies are evaluating 80+ Psoriasis pipeline therapies in various stages of development, and their anticipated acceptance in the Psoriasis market would significantly increase market revenue.

 

  • The leading Psoriasis Companies include Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.

 

  • Promising Psoriasis Pipeline Therapies include Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, LAS41004, Calcipotriene Foam, Talarozole, U0267, and others.

 

  • The Psoriasis companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The Psoriasis pipeline therapies under development are focused on novel approaches to treat/improve Psoriasis. 

 

To explore more information on the latest breakthroughs in the Psoriasis Pipeline treatment landscape of the report, click here @ Psoriasis Pipeline Outlook

 

Psoriasis Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis.

 

Recent Developmental Activities in the Psoriasis Treatment Landscape

 

  • In November 2020, Biohaven Pharmaceutical collaborates with Weill Cornell Medicine, to initiate a clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis. CGRP is a neuropeptide and believed to play an important role in the pathogenesis of inflammatory skin diseases such as psoriasis.

 

For further information, refer to the detailed Psoriasis Unmet Needs, Psoriasis Market Drivers, and Psoriasis Market Barriers, click here for Psoriasis Ongoing Clinical Trial Analysis

 

Psoriasis Emerging Drugs Profile 

 

  • Topical roflumilast: Arcutis Biotherapeutics

Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.

 

  • GSK2982772: GlaxoSmithKline

GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.

 

Psoriasis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.

 

Request a sample and discover the recent advances in Psoriasis Ongoing Clinical Trial Analysis and Medications, click here @ Psoriasis Treatment Landscape

 

Scope of the Psoriasis Pipeline Insight Report 

 

  • Coverage- Global

 

  • Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.

 

  • Psoriasis Pipeline Therapies- Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, LAS41004, Calcipotriene Foam, Talarozole, U0267, and others.

 

  • Psoriasis Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

 

Dive deep into rich insights for drugs for Psoriasis Market Drivers and Psoriasis Market Barriers, click here @ Psoriasis Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Psoriasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Psoriasis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Psoriasis Collaboration Deals
  9. Late Stage Products (Phase III)
  10. CT-P43: Celltrion
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. EDP1815: Evelo Biosciences
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. AZD0284: AstraZeneca
  17. Drug profiles in the detailed report…..
  18. Early Stage Products (Preclinical)
  19. AZD0284: AstraZeneca
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Psoriasis Key Companies
  23. Psoriasis Key Products
  24. Psoriasis- Unmet Needs
  25. Psoriasis- Market Drivers and Barriers
  26. Psoriasis- Future Perspectives and Conclusion
  27. Psoriasis Analyst Views
  28. Psoriasis Key Companies
  29. Appendix

 

Got Queries? Find out the related information on Psoriasis Mergers and acquisitions, Psoriasis Licensing Activities @ Psoriasis Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/